Cepheid Lowered to Neutral at JPMorgan Chase & Co. (CPHD)
Cepheid (NASDAQ:CPHD) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report issued on Tuesday, TheFlyOnTheWall.com reports.
A number of other analysts have also recently weighed in on CPHD. Analysts at Needham & Company initiated coverage on shares of Cepheid in a research note to investors on Thursday, December 19th. They set a “hold” rating on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Cepheid in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Cepheid from $44.00 to $48.00 in a research note to investors on Friday, December 13th. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. Cepheid currently has a consensus rating of “Hold” and a consensus target price of $43.26.
In other Cepheid news, EVP Kerry Flom unloaded 6,357 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $45.66, for a total transaction of $290,260.62. Following the completion of the transaction, the executive vice president now directly owns 20,000 shares of the company’s stock, valued at approximately $913,200. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Cepheid (NASDAQ:CPHD) traded up 0.37% during mid-day trading on Tuesday, hitting $46.02. 249,646 shares of the company’s stock traded hands. Cepheid has a 52-week low of $30.95 and a 52-week high of $47.21. The stock has a 50-day moving average of $45.33 and a 200-day moving average of $39.21. The company’s market cap is $3.122 billion.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.